Background: The majority of lung cancer patients are diagnosed with advanced non-small cell lung cancer (NSCLC), the bulk of which receive palliative systemic treatment with the goal to provide effect
Dataset of the paper: Reliability and applicability of the revised Cochrane risk-of-bias tool for randomised trials (RoB 2): low inter-rater reliability and challenges in application
